Melflufen therapy for heavily pretreated relapsed refractory multiple myeloma (RRMM) patients refractory to daratumumab and/or pomalidomide: Early efficacy data (Horizon) Meeting Abstract

  

Authors:	Mateos, M. V.; Oriol Rocafiguera, A.; Rodríguez-Otero, P.; Bladé, J.; Larocca, A.; Moreb, S. J.; Cavo, M.; Mazumder, A.; Alegre, A.; Hassoun, H.; Maisel, C.; Paner, A.; Gabrail, N.; Halka, K.; Zonder, J.; Ocio, E.; Byrne, C.; Harmenberg, J.; Lindberg, J.; Nordström, E.; Thuresson, S.; Richardson, G. P.
Abstract Title:	Melflufen therapy for heavily pretreated relapsed refractory multiple myeloma (RRMM) patients refractory to daratumumab and/or pomalidomide: Early efficacy data (Horizon)
Meeting Title:	1st European Myeloma Network Meeting
Journal Title:	Haematologica
Volume:	103
Issue:	Suppl. 1
Meeting Dates:	2018 Apr 19-21
Meeting Location:	Turin, Italy
ISSN:	0390-6078
Publisher:	Ferrata Storti Foundation
Date Published:	2018-04-18
Start Page:	32
Language:	English
ACCESSION:	WOS:000431395800069
PROVIDER:	wos
Notes:	Meeting Abstract: P40 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/125588